Abstract
Eighteen patients with advanced epidermoid carcinoma of the head and neck were entered into a phase II trial of N-Methylformamide (NMF), 800 mg/M2 IV daily for 5 days every 4 weeks. Seventeen patients had received prior radiation therapy and 11 were previously treated with chemotherapy. No complete or partial responses were observed. The major toxicity was gastrointestinal. Fifty percent of patients experienced nausea and vomiting or reversible hepatotoxicity with greater than a 3-fold elevation of liver enzymes. Mild reversible myelosuppression occurred in 2 patients. NMF in this dose and schedule was not a useful agent to treat recurrent epidermoid carcinoma of the head and neck.
Original language | English (US) |
---|---|
Pages (from-to) | 203-206 |
Number of pages | 4 |
Journal | Investigational New Drugs |
Volume | 5 |
Issue number | 2 |
DOIs | |
State | Published - Jun 1987 |
Externally published | Yes |
Keywords
- N-methylformamide
- head and neck cancer
- phase II trial
ASJC Scopus subject areas
- Oncology
- Pharmacology
- Pharmacology (medical)